Key result
A large number of new injectable and oral anticoagulant agents with unique mechanisms are in development and may soon be available for the management of thrombosis.
This review highlights the potential of emerging injectable and oral anticoagulant agents to improve upon the pharmacokinetic and pharmacodynamic limitations of current therapies.
Answers are grounded in this paper and cite their sources.
New anticoagulants should not alter current practice; leaves open their role in thrombosis pending randomized data.
Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.
No takes yet. Share an insight, caveat, or question.
Dobesh et al. (2004) conducted a review in Thrombosis. New anticoagulant agents was evaluated. A large number of new injectable and oral anticoagulant agents with unique mechanisms are in development and may soon be available for the management of thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: